Significant Revenue Growth This Fiscal Year and Launch of a Major Skincare Series
First written in FY2022-Q1. 7 of 18 entries say "Advanced", first in FY2022-Q2. Latest entry: 2026-07-01.
No other company in this theme has enough history to compare yet.
- 2026-07-01AdvancedRevision of earnings forecasts
「We have also been able to procure the raw materials for the 50th-anniversary commemorative product, a large skincare product, and now expect to launch it in the fourth quarter of the fiscal year ending March 2027.」
The company was able to procure raw materials for the large skincare product, making the launch outlook for the fourth quarter of the fiscal year ending March 2027 more specific. The original canonical thread remains unchanged. - FY2026WorsenedAnnual report
「Retail sales for the fiscal year under review were initially targeted at ¥9.20 billion, but amounted to ¥7.43 billion, representing a significant shortfall against the target.」
In the absence of major new products, sales at retail prices were ¥7.43 billion against a target of ¥9.2 billion, also declining from the previous fiscal year. Progress deteriorated against the previous expectations based on significant revenue growth. - FY2026-H1Modest revenue growth rather than significant revenue growthAnnual report
「As a result, revenue for the current interim accounting period increased 0.2% from the previous interim accounting period.」
Revenue increased only 0.2% year on year in the interim period, representing limited progress against the previous outlook for significant revenue growth. - FY2025WorsenedAnnual report
「Sales at retail prices, the company’s target metric, were ¥8,310 million, compared with ¥7,756 million in the previous fiscal year. Although this was below the medium-term target of ¥10,000 million, sales increased 7.2% from the previous fiscal year.」
Sales at retail prices increased 7.2% from the previous fiscal year but fell short of the medium-term target of ¥10 billion. - FY2025-H1WorsenedAnnual report
「Revenue for the current interim accounting period declined 7.8% from the previous interim accounting period, continuing to decrease.」
Against the revenue growth trend in the previous interim period, revenue declined 7.8% in the current interim period. The filing identifies lower orders for new products than in the previous interim period as a contributing factor. - FY2024-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter increased 2.2% from the same cumulative period of the previous year and continued to grow.」
Regarding the recovery in revenue following the launch of major new products, cumulative third-quarter revenue increased 2.2% year on year. Progress toward the previous expectation of significant revenue growth was limited, but revenue shifted from a decline in the same period of the previous year to an increase. - FY2024-Q2AdvancedAnnual report
「As a result, revenue for the cumulative second quarter increased 5.9% from the same cumulative period of the previous year and continued to grow.」
Regarding the recovery in revenue following the launch of new products, cumulative second-quarter revenue increased 5.9% year on year, marking continued revenue growth. However, sales of Red Power Serum were below the level of the same period of the previous year. - FY2024-Q1AdvancedAnnual report
「Regarding sales for the cumulative first quarter, orders for the newly launched Ivy Attracty facial cleanser series in June 2023, all of which are quasi-drugs, exceeded initial expectations. Production could not keep pace, and some shipments were deferred to the second quarter. As a result, revenue for the cumulative first quarter increased 47.8% from the same cumulative period of the previous year and continued to grow.」
Regarding the recovery in revenue based on major new products, orders for Ivy Attracty exceeded expectations, and first-quarter revenue increased 47.8% year on year. - FY2023WorsenedAnnual report
「The company initially targeted ¥11 billion in sales at retail prices for the fiscal year, but the result was ¥8.1 billion, compared with ¥10 billion in the previous fiscal year, representing a significant shortfall against the target.」
Against the expectation of significant revenue growth following the launch of major new products, sales at retail prices fell short of the ¥11 billion target and also declined from the previous fiscal year. - FY2023-Q3WorsenedAnnual report
「As a result, for the cumulative third quarter, net sales were ¥1,689.891 million, down 25.4% year on year, operating loss was ¥412.277 million, compared with an operating loss of ¥141.571 million in the same quarter of the previous year, and ordinary loss was ¥414.948 million, compared with an ordinary loss of ¥138.790 million. After recording a negative tax expense of ¥78.505 million, including a ¥87.438 million negative adjustment to income taxes and other taxes, net loss for the quarter was ¥418.826 million, compared with a net loss of ¥143.104 million.」
Against the previous outlook for revenue growth based on the launch of major new products, cumulative third-quarter revenue declined 25.4%, while operating, ordinary and net losses all widened from the same period of the previous year. - FY2023-Q2Reversal from expected significant revenue growth to declining revenueAnnual report
「As a result, revenue for the cumulative second quarter was ¥1,414.475 million, down 27.3% from the same cumulative period of the previous year. The company recorded an operating loss of ¥62.608 million, compared with operating income of ¥272.869 million in the same quarter of the previous year, an ordinary loss of ¥64.263 million, compared with ordinary income of ¥271.433 million, and a quarterly net loss of ¥59.389 million, compared with quarterly net income of ¥197.350 million in the same cumulative period.」
Against the previous expectation of significant revenue growth based on the launch of the major skincare series, revenue for the cumulative second quarter declined 27.3%, and operating income, ordinary income and net income all turned into losses. - FY2022SoftenedAnnual report
「Sales of serums and new skincare products did not reach the expected level. Revenue for the fiscal year was ¥3,534.133 million, up 3.1% from the previous fiscal year.」
Following the launch of the major skincare series, full-year revenue increased, but growth was limited to 3.1%, and sales of serums and new skincare products did not reach the expected level. - FY2022-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter was ¥2,266.403 million, up 11.9% year on year.」
Following the launch of the major skincare series, cumulative third-quarter revenue increased 11.9% year on year. Although the growth rate declined from the previous quarter’s 35.1%, revenue continued to increase. - FY2022-Q2AdvancedAnnual report
「As a result, although sales fell short of the initial budget, revenue for the cumulative second quarter increased 35.1% year on year.」
Following the launch of the major skincare series, revenue increased 35.1% year on year despite falling short of the initial budget, indicating progress toward the expected significant revenue growth for the current fiscal year. - FY2022-Q1First statedAnnual report
「In addition, the company plans to launch the major Ivy Cosmos II skincare series this autumn. The product has already received a highly favorable reception, and sales for the current fiscal year are expected to increase significantly from the previous fiscal year.」
The company newly indicates that sales for the current fiscal year are expected to increase significantly from the previous fiscal year, based on the launch of the major skincare series this autumn.